Androgen-regulated transcriptional control of sialyltransferases in prostate cancer cells.

PloS One
Koji HatanoYasufumi Kaneda

Abstract

The expression of gangliosides is often associated with cancer progression. Sialyltransferases have received much attention in terms of their relationship with cancer because they modulate the expression of gangliosides. We previously demonstrated that GD1a production was high in castration-resistant prostate cancer cell lines, PC3 and DU145, mainly due to their high expression of β-galactoside α2,3-sialyltransferase (ST3Gal) II (not ST3Gal I), and the expression of both ST3Gals was regulated by NF-κB, mainly by RelB. We herein demonstrate that GD1a was produced in abundance in cancerous tissue samples from human patients with hormone-sensitive prostate cancers as well as castration-resistant prostate cancers. The expression of ST3Gal II was constitutively activated in castration-resistant prostate cancer cell lines, PC3 and DU145, because of the hypomethylation of CpG island in its promoter. However, in androgen-depleted LNCap cells, a hormone-sensitive prostate cancer cell line, the expression of ST3Gal II was silenced because of the hypermethylation of the promoter region. The expression of ST3Gal II in LNCap cells increased with testosterone treatment because of the demethylation of the CpG sites. This testosterone-dependen...Continue Reading

References

Apr 1, 1992·Current Opinion in Cell Biology·A Varki
Feb 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·A N HoughtonL J Old
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Jul 1, 1996·Journal of Biochemistry·S Tsuji
Oct 23, 1997·International Journal of Cancer. Journal International Du Cancer·S ZhangP O Livingston
Jul 21, 1999·Journal of the National Cancer Institute·M O RippleR Weindruch
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·T YamashitaR L Proia
May 16, 2001·Biochemical and Biophysical Research Communications·Z LangS Ladisch
Aug 30, 2001·Hematology/oncology Clinics of North America·F A Ferrer, R Rodriguez
Sep 6, 2001·The Journal of Biological Chemistry·R LiS Ladisch
Aug 1, 2002·Proceedings of the National Academy of Sciences of the United States of America·Senitiroh Hakomori
Dec 31, 2002·Biochemical and Biophysical Research Communications·Akiyoshi TaniguchiKojiro Matsumoto
May 29, 2003·Biochimie·S BirkléJ Aubry
Jun 25, 2003·Glycoconjugate Journal·F Dall'Olio, M Chiricolo
Apr 15, 2004·Endocrine Reviews·Cynthia A Heinlein, Chawnshang Chang
Jun 25, 2004·The Journal of Biological Chemistry·Yihui LiuStephan Ladisch
Oct 7, 2004·Biochemical and Biophysical Research Communications·Mepur H RavindranathDonald L Morton
Apr 9, 2005·International Journal of Cancer. Journal International Du Cancer·Mepur H RavindranathDonald L Morton
Jul 29, 2005·Nature·Andy J MinnJoan Massagué
Apr 1, 2006·Glycoconjugate Journal·Enrique Villar, Isabel Muñoz Barroso
Mar 14, 2007·Analytical Biochemistry·Hiroaki KorekaneYasuhide Miyamoto
Apr 5, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Svend O FreytagJae Ho Kim
Jul 17, 2007·Laboratory Investigation; a Journal of Technical Methods and Pathology·Nissi M Varki, Ajit Varki
Mar 7, 2008·Nature·Raphaël MétivierGilles Salbert
Mar 7, 2008·Nature·Sara KangaspeskaGeorge Reid
May 8, 2008·Bioscience, Biotechnology, and Biochemistry·Shou Takashima
Jan 29, 2009·International Journal of Cancer. Journal International Du Cancer·Yoshifumi KawaguchiYasufumi Kaneda
May 8, 2009·Nature·Paula D BosJoan Massagué
May 28, 2009·Proceedings of the National Academy of Sciences of the United States of America·Kimihiro YoshimuraShigeaki Kato
Jun 13, 2009·Endocrinology·William G NelsonSrinivasan Yegnasubramanian
Oct 16, 2009·Nature·Mi-Sun KimShigeaki Kato

❮ Previous
Next ❯

Citations

Jun 21, 2014·Biochimica Et Biophysica Acta·Fabio Dall'OlioMariella Chiricolo
Apr 20, 2016·Nature Reviews. Urology·Jennifer MunkleyDavid J Elliott
May 10, 2017·International Journal of Molecular Sciences·Fabio Dall'Olio, Marco Trinchera
Apr 29, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jishun Lu, Jianguo Gu
Mar 22, 2019·International Journal of Molecular Sciences·Emma Scott, Jennifer Munkley
Sep 30, 2016·Medicinal Research Reviews·Rémi Szabo, Danielle Skropeta
May 17, 2014·Cancer Research·Christian BüllGosse J Adema

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
electrophoresis
biopsy

Software Mentioned

ImageQuant
ImageQuant TL
Methyl Primer Express
StatView

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Alzheimer's Disease: Transcription

Impaired transcription is associated with the pathogenesis and progression of conditions such as Alzheimer's disease (AD). Here are the latest discoveries pertaining to transcription and AD.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.